Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | MYC | P01106 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | TPMT | P51580 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL182820 | 0.85 | ALDH1A1 (0.49) | ALDH1A1KDM4EHTTHPGDMAPT | |
| SCHEMBL8317114 | 0.85 | HTT (0.44) | ALDH1A1KDM4EHTTHPGDMAPT | |
| SCHEMBL2551636 | 0.83 | PARP10 (0.41) | ALDH1A1KDM4EHTTHPGDMAPT | |
| SCHEMBL2443988 | 0.83 | GAA (0.45) | ALDH1A1KDM4EHTTHPGDMAPT | |
| SCHEMBL6200251 | 0.81 | KDM4E (0.58) | ALDH1A1KDM4EHPGDMAPTTDP1 | |
| SCHEMBL2552993 | 0.80 | MAPT (0.37) | ALDH1A1HTTHPGDMAPTNPSR1 | |
| SCHEMBL2554120 | 0.80 | PLK1 (0.49) | ALDH1A1KDM4EHTTHPGDMAPT | |
| SCHEMBL4319075 | 0.80 | ALDH1A1 (0.46) | ALDH1A1KDM4EHPGDTDP1HSD17B10 | |
| SCHEMBL4318856 | 0.80 | TSHR (0.47) | ALDH1A1KDM4EHTTHSD17B10KMT2A | |
| SCHEMBL1809516 | 0.78 | TSHR (0.49) | ALDH1A1KDM4EHPGDMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739083-B2 | Disposable sensor chip with reagent including 2-substituted benzothiazolyl-3-substituted phenyl-5-substituted sulfonated phenyl-2H-tetrazolium salt | TERUMO KABUSHIKI KAISHA (JP) | 2023-08-29 | — | — | US | claimed |
| US-20230122243-A1 | Heteroaromatic inhibitors of astacin proteinases | VIVORYON THERAPEUTICS N.V. (DE) | 2023-04-20 | — | — | US | claimed |
| CN-109689648-B | 2-substituted benzothiazolyl-3-substituted phenyl-5-substituted sulfonated phenyl-2H-tetrazolium salt | 泰尔茂株式会社 | 2022-07-26 | — | — | CN | claimed |
| CN-114585608-A | Heteroaromatic inhibitors of astacin protease | 维沃永治疗公众有限公司 | 2022-06-03 | — | — | CN | claimed |
| CN-114507175-A | Novel inhibitors of hypnotic proteins alpha and beta | 维沃里翁治疗股份有限公司 | 2022-05-17 | — | — | CN | claimed |
| EP-3986868-A1 | HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES | Vivoryon Therapeutics N.V. (DE) | 2022-04-27 | — | — | EP | claimed |
| CN-109195947-B | Novel inhibitors of hypnotic proteins alpha and beta | 维沃里翁治疗股份有限公司 | 2022-03-04 | — | — | CN | claimed |
| EP-3445744-B1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | VIVORYON THERAPEUTICS AG (DE) | 2021-10-06 | — | — | EP | claimed |
| US-20210198189-A1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | VIVORYON THERAPEUTICS AG (DE) | 2021-07-01 | — | — | US | claimed |
| US-10975019-B2 | Inhibitors of meprin α and β | VIVORYON THERAPEUTICS AG (DE) | 2021-04-13 | — | — | US | claimed |
| EP-1633716-A4 | BIARYLMETHYL INDOLINES, INDOLES AND TETRAHYDROQUINOLINES, USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-03-26 | — | — | EP | claimed |
| US-20070032482-A1 | Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-02-08 | — | — | US | claimed |
| US-7129264-B2 | Biarylmethyl indolines and indoles as antithromboembolic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-31 | — | — | US | claimed |
| CN-1829709-A | Bicyclic imidazol derivatives against flaviviridae | GENELABS TECH INC (US) | 2006-09-06 | — | — | CN | claimed |
| EP-1648886-A1 | BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-04-26 | — | — | EP | claimed |
| EP-1633716-A2 | BIARYLMETHYL INDOLINES, INDOLES AND TETRAHYDROQUINOLINES, USEFUL AS SERINE PROTEASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-03-15 | — | — | EP | claimed |
| US-20050245555-A1 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-11-03 | — | — | US | claimed |
| WO-2005014589-A1 | BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (DE) | 2005-02-17 | — | — | WO | claimed |
| WO-2004094372-A2 | COMPOUNDS USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | claimed |
| US-20040220206-A1 | Biarylmethyl indolines, indoles and tetrahydroquinolines, useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245555-A1 | Tri-substituted ureas as cytokine inhibitors | IL1B, IL1A, IL6 | ALDH1A1 455/4885KDM4E 2087/4885HTT 1854/4885 |
| US-20230122243-A1 | Heteroaromatic inhibitors of astacin proteinases | BMP1, DPEP1, MEP1A | ALDH1A1 2800/4885KDM4E 2174/4885HTT 2952/4885 |
| US-20040220206-A1 | Biarylmethyl indolines, indoles and tetrahydroquinolines, useful as serine protease inhibitors | TFPI, TFPI2, F2 | ALDH1A1 2594/4885KDM4E 1323/4885HTT 4087/4885 |
| US-20070032482-A1 | Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments | HTR6, HTR5A, P2RX6 | ALDH1A1 1597/4885KDM4E 1795/4885HTT 2828/4885 |
| US-11739083-B2 | Disposable sensor chip with reagent including 2-substituted benzothiazolyl-3-substituted phenyl-5-substituted sulfonated phenyl-2H-tetrazolium salt | STUB1, BTK, TST | ALDH1A1 663/4885KDM4E 1035/4885HTT 827/4885 |
| US-20210198189-A1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | MEP1A, MEP1B, CAPRIN1 | ALDH1A1 3469/4885KDM4E 3258/4885HTT 1859/4885 |
| US-10975019-B2 | Inhibitors of meprin α and β | MEP1A, MEP1B, CAPRIN1 | ALDH1A1 3070/4885KDM4E 2394/4885HTT 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.